ChemMedChem · 2015 · 30 citations · 19 references
MedicineMedicinal ChemistryPharmacologyBiomedical ImagingDrug DesignMolecular ImagingMolecular Imaging In OncologyPositron Emission TomographyRadiopharmaceutical DesignRadiopharmaceutical TherapyRadiotracer DevelopmentTargeted Imaging AgentsFluorine-18 ChemistryFluorine-18 RadiopharmaceuticalsMolecular Imaging Probe DesignPet RadiopharmaceuticalsPet TracersRadiotracer SynthesisRadiotracers Targeting CyclooxygenaseSelective Cyclooxygenase-2 Inhibitors
A series of novel fluorine-containing cyclooxygenase-2 (COX-2) inhibitors was designed and synthesized based on the previously reported fluorescent COX-2 imaging agent celecoxib-NBD (3; NBD=7-nitrobenzofurazan). In vitro COX-1/COX-2 inhibitory data show that N-(4-fluorobenzyl)-4-(5-p-tolyl-3-trifluoromethylpyrazol-1-yl)benzenesulfonamide (5; IC50 =0.36 μM, SI>277) and N-fluoromethyl-4-(5-p-tolyl-3-trifluoromethylpyrazol-1-yl)benzenesulfonamide (6; IC50 =0.24 μM, SI>416) are potent and selective COX-2 inhibitors. Compound 5 was selected for radiolabeling with the short-lived positron emitter fluorine-18 ((18) F) and evaluated as a positron emission tomography (PET) imaging agent. Radiotracer [(18) F]5 was analyzed in vitro and in vivo using human colorectal cancer model HCA-7. Although radiotracer uptake into COX-2-expressing HCA-7 cells was high, no evidence for COX-2-specific binding was found. Radiotracer uptake into HCA-7 tumors in vivo was low and similar to that of muscle, used as reference tissue.
19
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
Ravi G. Kurumbail, Anna M. Stevens, James K. Gierse et al. · Nature · 1996 · 1.9K citations
Aspirin use and risk of fatal cancer.
Michael J. Thun, M M Namboodiri, Eugenia E. Calle et al. · PubMed · 1993 · 869 citations
Medicine, Oncology, Pharmacology +14